In a patient with heart failure with reduced ejection fraction and hypertension, is lercanidipine appropriate for blood pressure control?

Lercanidipine is NOT appropriate for blood pressure control in patients with HFrEF and should be avoided.

In patients with heart failure with reduced ejection fraction (HFrEF) and hypertension, dihydropyridine calcium channel blockers like lercanidipine may be used ONLY after maximizing guideline-directed medical therapy (GDMT), but they are not first-line agents and offer no mortality benefit.

Treatment Algorithm for BP Control in HFrEF

First-Line Approach: Optimize GDMT

The 2025 AHA/ACC guidelines explicitly state that uptitration of HF GDMT to maximally tolerated doses is the recommended strategy for hypertension control in HFrEF 1. This means:

1. ACE inhibitors/ARBs or ARNIs (angiotensin receptor-neprilysin inhibitors)
2. Evidence-based beta-blockers (carvedilol, metoprolol succinate, bisoprolol)
3. Mineralocorticoid receptor antagonists (spironolactone, eplerenone)
4. SGLT2 inhibitors (dapagliflozin, empagliflozin)

These four pillars reduce mortality and HF hospitalizations while simultaneously lowering blood pressure 1, 2, 3.

Target Blood Pressure

• Aim for systolic BP <130 mmHg 1
• Do not let low blood pressure deter uptitration of GDMT if the patient tolerates it without adverse events 4

When to Consider Dihydropyridine CCBs (Including Lercanidipine)

Only after GDMT optimization: If blood pressure remains elevated despite maximally tolerated doses of the four GDMT pillars, dihydropyridine calcium channel blockers may be added 1.

The 2025 AHA/ACC guidelines state: "Dihydropyridine CCB may be used to treat hypertension in patients with elevated BP despite the optimization of GDMT" 1.

Critical Caveats

• Nondihydropyridine CCBs are contraindicated in HFrEF due to negative inotropic effects 1
• Lercanidipine, while a dihydropyridine, provides no prognostic benefit in HFrEF—it only lowers BP 5
• The evidence for lercanidipine specifically in HFrEF is absent; studies only demonstrate efficacy in general hypertension populations 5, 6
• Diuretics should be added as needed for volume overload before considering additional vasodilators 1

Practical Implementation

Step 1: Maximize GDMT

• Uptitrate ACEi/ARB/ARNi to target doses
• Uptitrate beta-blocker to target doses
• Add MRA (spironolactone 25-50mg or eplerenone)
• Initiate SGLT2 inhibitor

Step 2: Assess Volume Status

• If volume overloaded: optimize diuretic therapy first 1
• Loop diuretics or thiazide-like diuretics as appropriate

Step 3: If BP Still Elevated

• Only then consider adding lercanidipine or another dihydropyridine CCB
• Typical lercanidipine dosing: 10-20mg once daily 5, 6

Common Pitfalls to Avoid

1. Using lercanidipine as first-line therapy instead of GDMT—this misses the opportunity to reduce mortality
2. Stopping GDMT due to low BP readings when the patient is asymptomatic—lower BP in HFrEF may actually indicate better outcomes when achieved with GDMT 4, 7
3. Confusing dihydropyridine with nondihydropyridine CCBs—the latter (diltiazem, verapamil) are harmful in HFrEF 1
4. Inadequate diuretic optimization before adding vasodilators

Bottom Line

Lercanidipine is a third-line option at best for BP control in HFrEF. Prioritize the four GDMT pillars that save lives, then optimize diuretics, and only consider lercanidipine if BP remains uncontrolled 1. The 2024 ESC guidelines similarly emphasize RAAS inhibition, beta-blockers, and MRAs as foundational therapy 8, with CCBs reserved for resistant cases.